NASD · Healthcare · Diagnostics & Research · USA
Natera Inc is a large cap company (market value between $10 billion and $200 billion) in the Diagnostics & Research industry.
Natera is a diagnostics company applying proprietary cell-free DNA technology and bioinformatics to oncology, women's health, and organ health. The company offers blood-based tests for cancer monitoring and recurrence detection, prenatal testing and hereditary cancer screening, and transplant rejection assessment. It commercializes these tests through direct sales and a global network of laboratory and distribution partners.
From its FY2025 annual report (Form 10-K)
Intrinsic value, DCF valuation, financial health and value investing analysis for the Natera Inc stock.
Overvalued: intrinsic value $58.09 per share, market price $399.42, margin of safety -587.5% (as of 2026-10-19).
A 2.7x revenue multiple, discounted for its losses, values the shares at $58.09; the price of $399.42 is 588% above that value.
Leak Score: 36/100 on 10 of 12 signals (On Watch).
17 more funds hold it; the full list is part of the paid plan.
All 44 Diagnostics & Research stocks
20 more in this industry show a wider margin of safety.
NTRA is overvalued (as of the 2026-10-19 close). A 2.7x revenue multiple, discounted for its losses, values the shares at $58.09; the price of $399.42 is 588% above that value.
$58.09 per share (as of the 2026-10-19 close), against a market price of $399.42. That is a margin of safety of -587.5%. The value is the average of the valuation methods that apply to this company, recomputed every night after the US close.
The price pays more for each dollar of sales than its growth and margins justify. Times its sales the price pays: 20.9x. Multiple we apply for its growth and margins: 2.7x.
36 out of 100, which we rate "On Watch", on 10 of 12 value investing signals.